A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers

NCT05213728 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
8
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Vaxart